As the largest healthcare company in France, Sanofi has participated in the China International Import Expo for the seventh consecutive year. Benefiting from the spillover effect of the CIIE, Sanofi showcased its global R&D pipeline, which includes 12 potential heavyweight products, as well as 7 innovative achievements in the field of immunology at this year's CIIE. In addition, Sanofi announced further promotion of localization, reached a strategic cooperation with Shangyao Holdings, and signed a series of contracts.
Sanofi CEO Paul Hudson said that the CIIE provides an important platform for Sanofi, which not only promotes further opening up of the Chinese market, but also creates more opportunities for potential cooperation between various fields around the world. Sanofi aims to transform the medical model and deeply understands the scale and speed of innovation in China. We look forward to supporting the development of China's world-class medical ecosystem and benefiting patients worldwide.
Sanofi's star product in the field of immune inflammation, Dabitou& reg; He is one of the witnesses and witnesses of 'China's speed'. In September of this year, Dabitou& reg; The new indication for chronic obstructive pulmonary disease has been approved in China, and it is reported that this approval was granted before the approval of the US FDA. Compared to the European Union and the United States, China has the shortest approval time, once again breaking the record for innovative drugs benefiting Chinese patients. Its other product, Saiyining& reg; In 2021, we will participate in the CIIE and embark on our journey in China. In just one year, we will achieve a "three-level leap" from approval, listing to inclusion in medical insurance at the "Chinese speed" in 2023.
Sanofi Greater China President Shi Wang stated that in the past seven years, thanks to the strong "spillover effect" of the CIIE, Sanofi's business development in China has indeed accelerated. We have also witnessed the Chinese government's firm commitment to promoting pharmaceutical innovation and health through the CIIE. This year, we will once again attend the meeting with multiple innovative achievements in the field of immunology that are "first" or "only" in China and globally, and further deepen cooperation and dialogue with local partners. The Chinese market is crucial to Sanofi, and we always focus on the unmet medical needs of patients, continuously strengthen investment in scientific innovation, business model innovation, and actively build a Chinese pharmaceutical and health innovation ecosystem, and help promote the high-quality development of the industry
During the CIIE, Sanofi announced a strategic partnership with Shangyao Holdings. Based on the good cooperation foundation in the past, both parties will expand their cooperation in the pharmaceutical business field, optimize cooperation models, improve operational efficiency, focus on key products, enhance market accessibility, and promote higher-level industrial chain innovation and cross integration. This is one of the largest, most extensive, and deepest strategic partnerships between the pharmaceutical industry and industry, marking a new step for Sanofi and Shangyao Holdings in promoting collaborative innovation and development in the pharmaceutical industry.
During the CIIE, Sanofi held multiple important signing ceremonies and events at its booth, continuously exploring and practicing localization, increasing investment and layout in the Chinese market. It also signed a memorandum of cooperation with Kaihui Fund to help develop China's pharmaceutical innovation ecosystem, achieve technological breakthroughs and commercial success, and unleash the global potential of Chinese innovation; Signed a strategic cooperation agreement with Tianjing Biotechnology regarding the development, production, and commercialization of the CD73 antibody uliledlimab in Greater China.